Severe Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA)

Simple item page
dc.contributor.authorWhite N.J.
dc.contributor.authorWatson J.A.
dc.contributor.authorSimpson J.A.
dc.contributor.otherMahidol University
dc.date.accessioned2023-06-18T17:47:19Z
dc.date.available2023-06-18T17:47:19Z
dc.date.issued2022-07-15
dc.identifier.citationClinical Infectious Diseases Vol.75 No.2 (2022) , 358
dc.identifier.doi10.1093/cid/ciac024
dc.identifier.eissn15376591
dc.identifier.issn10584838
dc.identifier.pmid35023549
dc.identifier.scopus2-s2.0-85137124619
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/85716
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleSevere Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA)
dc.typeLetter
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137124619&origin=inward
oaire.citation.issue2
oaire.citation.titleClinical Infectious Diseases
oaire.citation.volume75
oairecerif.author.affiliationMahidol Oxford Tropical Medicine Research Unit
oairecerif.author.affiliationMelbourne School of Population and Global Health

Files

Collections

Scopus 2022